Search
From www.nytimes.com
5 min read
FDA Approves Zarxio, First Biosimilar Drug
The approval paves the way for alternatives to an entire class of complex and costly drugs to go on the market. Most brand-name drugs...
Nick Dutnall
3 min read
Putting our lives in their brands
From www.theguardian.com What if brand loyalty was actually as serious as life and death? Nick Dutnall looks at how we might trust a...
Megan Hillen
2 min read
Making medicine emotional
from www.mmm-online.com Since the birth of branding, and particularly in the advent of the “like,” people have been using brands as a...
Jennifer McKenzie and Amy Dam / Bereskin &Parr LLP
2 min read
Update on pharmaceutical brand name requirements in Canada
Sponsors filing a drug submission must also provide a brand name assessment as part of the drug safety and effectiveness evaluation. The...
Meg Tirrell | Eric Chemi | Mark Fahey / CBNC
4 min read
What's in a name? For drugs, a lot of Zs and Xs
Farxiga. Hetlioz. Otezla. Zykadia. No, these are not the names of distant planets visited by the starship Enterprise. They're the brand...
By Beth Snyder Bulik / FiercePharmaMarketing
2 min read
Back-to-'Biogen' shift signals wider industry branding trend
Biogen's ($BIIB) recent change back to its original name - from the decade-old merger name Biogen Idec - made sense in many ways. Along...
Jennifer Rankin / The Guardian
3 min read
Cancer breakthroughs trigger big pharma interest in drugs and deals
Companies are scrambling to get into the immunotherapy market, which experts think could eventually be worth up to £26bn a year in sales....
By David Coleiro and Michael White / eye for
5 min read
Defining brands and why they are critical to success in healthcare.
As we start our column in earnest, we thought we should perhaps state our position, be clear on some boundaries and definitions of what...
By Donald G. McNeil Jr. /
4 min read
The Science of Naming Drugs (Sorry, 'Z' Is Already Taken)
Not only is the process of christening a new product a lot trickier than it sounds, the most obvious candidates can be the most perilous....
by John Phillips, Director
3 min read
Biosimilars: Making the most of an “inexact” science
There’s no question that biosimilars are a revolution in life sciences. The development of these complex medications made from living...